Stem Cell Therapeutics Corp. Announces the Issuance of United States Patent Relating to Prolactin

   Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") is pleased to announce today that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,884,072- entitled, "Prolactin induced increase in neural stem cell number." The claims contained within this issued patent cover methods of using an effective amount of prolactin to increase stem cell numbers in mammals suspected of having neurological diseases.

Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows:

"This issued patent and other anticipated patents for the use of prolactin greatly assist the protection and capture of shareholder value for this therapeutic program. The important exclusivity that has been granted for the use of prolactin today combined with ever increasing scientific evidence supporting the use of prolactin builds upon the wealth of intellectual property that SCT possesses. We look forward to the continued advancement of this program in the future."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO 403-245-5495 ext.226 [e-mail] Stem Cell Therapeutics Corp. Michael Cook CFO 403-245-5495 ext.229 [e-mail] Stem Cell Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager 403-245-5495 ext. 230 [e-mail] www.stemcellthera.com